AVIR
HEALTHCAREAtea Pharmaceuticals Inc
$5.65+0.05 (+0.89%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving AVIR Today?
No stock-specific AI insight has been generated for AVIR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.46$6.45
$5.65
Fundamentals
Market Cap$452M
P/E Ratio—
EPS$-1.94
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume271K
Avg Volume (10D)—
Shares Outstanding80.0M
AVIR News
20 articles- Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026Yahoo Finance·May 5, 2026
- Atea Pharmaceuticals, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 6, 2026
- Atea Pharmaceuticals Inc (AVIR) Q4 2025 Earnings Call Highlights: Advancing HCV Treatments and ...Yahoo Finance·Mar 6, 2026
- Atea Pharmaceuticals Q4 Earnings Call HighlightsMarketbeat·Mar 5, 2026
- Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 5, 2026
- Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026Yahoo Finance·Feb 26, 2026
- Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026Yahoo Finance·Feb 24, 2026
- CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a TurnaroundMotley Fool·Feb 3, 2026
- Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.Motley Fool·Feb 3, 2026
- Spotlight On Atea Pharmaceuticals And 2 Other Noteworthy Penny StocksYahoo Finance·Jan 23, 2026
- JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimensPharmaceutical-technology·Jan 19, 2026
- Atea Pharmaceuticals Highlights Phase 3 HCV Timeline, Unveils New Hepatitis E Candidate AT-587 at JPMorgan ConferenceMarketbeat·Jan 15, 2026
- Bullish Atea Pharmaceuticals Insiders Loaded Up On US$5.40m Of StockYahoo Finance·Jan 13, 2026
- Atea Pharmaceuticals to highlight strategic priorities for FY26Yahoo Finance·Jan 9, 2026
- Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Jan 8, 2026
- Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Jan 6, 2026
- Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C VirusYahoo Finance·Dec 22, 2025
- Nano Dimension And 2 Other Penny Stocks With Promising PotentialYahoo Finance·Dec 17, 2025
- We're Keeping An Eye On Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn RateYahoo Finance·Dec 10, 2025
- ReAlta Life Sciences Designates Dr. Howard Berman as Executive ChairmanYahoo Finance·Dec 2, 2025
All 20 articles loaded
Price Data
Open$5.62
Previous Close$5.60
Day High$5.62
Day Low$5.54
52 Week High$6.45
52 Week Low$2.46
52-Week Range
$2.46$6.45
$5.65
Fundamentals
Market Cap$452M
P/E Ratio—
EPS$-1.94
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume271K
Avg Volume (10D)—
Shares Outstanding80.0M
About Atea Pharmaceuticals Inc
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapies for patients suffering from viral infections. The company is headquartered in Boston, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—